-
Comparison of neuromuscular fatigue in chronic stroke patients with healthy controls
Shweta Kotwani, Sharmishtha Gadgil and Parag Ranade
Research Article: Clinical Investigation
-
Comparison of neuromuscular fatigue in chronic stroke patients with healthy controls
Shweta Kotwani, Sharmishtha Gadgil and Parag Ranade
Research Article: Clinical Investigation
-
Comparison of neuromuscular fatigue in chronic stroke patients with healthy controls
Shweta Kotwani, Sharmishtha Gadgil and Parag Ranade
Research Article: Clinical Investigation
-
Comparison of neuromuscular fatigue in chronic stroke patients with healthy controls
Shweta Kotwani, Sharmishtha Gadgil and Parag Ranade
Research Article: Clinical Investigation
-
Comparison of neuromuscular fatigue in chronic stroke patients with healthy controls
Shweta Kotwani, Sharmishtha Gadgil and Parag Ranade
Research Article: Clinical Investigation
-
Comparison of neuromuscular fatigue in chronic stroke patients with healthy controls
Shweta Kotwani, Sharmishtha Gadgil and Parag Ranade
Research Article: Clinical Investigation
-
Comparison of neuromuscular fatigue in chronic stroke patients with healthy controls
Shweta Kotwani, Sharmishtha Gadgil and Parag Ranade
Research Article: Clinical Investigation
-
Comparison of neuromuscular fatigue in chronic stroke patients with healthy controls
Shweta Kotwani, Sharmishtha Gadgil and Parag Ranade
Research Article: Clinical Investigation
-
Recent trial results in recombinant coagulation factors for the treatment of hemophilia B
Julie Jaffray & Guy Young
Clinical Trail Outcomes: Clinical Investigation
-
Recent trial results in recombinant coagulation factors for the treatment of hemophilia B
Julie Jaffray & Guy Young
Clinical Trail Outcomes: Clinical Investigation
-
Recent trial results in recombinant coagulation factors for the treatment of hemophilia B
Julie Jaffray & Guy Young
Clinical Trail Outcomes: Clinical Investigation
-
Recent trial results in recombinant coagulation factors for the treatment of hemophilia B
Julie Jaffray & Guy Young
Clinical Trail Outcomes: Clinical Investigation
-
Recent trial results in recombinant coagulation factors for the treatment of hemophilia B
Julie Jaffray & Guy Young
Clinical Trail Outcomes: Clinical Investigation
-
Recent trial results in recombinant coagulation factors for the treatment of hemophilia B
Julie Jaffray & Guy Young
Clinical Trail Outcomes: Clinical Investigation
-
Recent trial results in recombinant coagulation factors for the treatment of hemophilia B
Julie Jaffray & Guy Young
Clinical Trail Outcomes: Clinical Investigation
-
Recent trial results in recombinant coagulation factors for the treatment of hemophilia B
Julie Jaffray & Guy Young
Clinical Trail Outcomes: Clinical Investigation
-
Ramucirumab: a promising development in advanced non-small cell lung cancer
Virginie Avrillon & Maurice Perol
Clinical Trail Outcomes: Clinical Investigation
-
Ramucirumab: a promising development in advanced non-small cell lung cancer
Virginie Avrillon & Maurice Perol
Clinical Trail Outcomes: Clinical Investigation
-
Ramucirumab: a promising development in advanced non-small cell lung cancer
Virginie Avrillon & Maurice Perol
Clinical Trail Outcomes: Clinical Investigation
-
Ramucirumab: a promising development in advanced non-small cell lung cancer
Virginie Avrillon & Maurice Perol
Clinical Trail Outcomes: Clinical Investigation
-
Ramucirumab: a promising development in advanced non-small cell lung cancer
Virginie Avrillon & Maurice Perol
Clinical Trail Outcomes: Clinical Investigation
-
Ramucirumab: a promising development in advanced non-small cell lung cancer
Virginie Avrillon & Maurice Perol
Clinical Trail Outcomes: Clinical Investigation
-
Ramucirumab: a promising development in advanced non-small cell lung cancer
Virginie Avrillon & Maurice Perol
Clinical Trail Outcomes: Clinical Investigation
-
Ramucirumab: a promising development in advanced non-small cell lung cancer
Virginie Avrillon & Maurice Perol
Clinical Trail Outcomes: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
What should be the primary end point in irritable bowel syndrome?
Allen W Mangel
Clinical Trail Prospective: Clinical Investigation
-
What should be the primary end point in irritable bowel syndrome?
Allen W Mangel
Clinical Trail Prospective: Clinical Investigation
-
What should be the primary end point in irritable bowel syndrome?
Allen W Mangel
Clinical Trail Prospective: Clinical Investigation
-
What should be the primary end point in irritable bowel syndrome?
Allen W Mangel
Clinical Trail Prospective: Clinical Investigation
-
What should be the primary end point in irritable bowel syndrome?
Allen W Mangel
Clinical Trail Prospective: Clinical Investigation
-
What should be the primary end point in irritable bowel syndrome?
Allen W Mangel
Clinical Trail Prospective: Clinical Investigation
-
What should be the primary end point in irritable bowel syndrome?
Allen W Mangel
Clinical Trail Prospective: Clinical Investigation
-
What should be the primary end point in irritable bowel syndrome?
Allen W Mangel
Clinical Trail Prospective: Clinical Investigation
-
Erratum
Erratum: Clinical Investigation
-
Erratum
Erratum: Clinical Investigation
-
Erratum
Erratum: Clinical Investigation
-
Erratum
Erratum: Clinical Investigation
-
Erratum
Erratum: Clinical Investigation
-
Erratum
Erratum: Clinical Investigation
-
Erratum
Erratum: Clinical Investigation
-
Erratum
Erratum: Clinical Investigation
-
The rationale and evidence for triple antiplatelet therapy in acute coronary syndromes
Beau M Hawkins, Jorge F Saucedo, Sunil V Rao
Review Article: Clinical Investigation
-
The rationale and evidence for triple antiplatelet therapy in acute coronary syndromes
Beau M Hawkins, Jorge F Saucedo, Sunil V Rao
Review Article: Clinical Investigation
-
The rationale and evidence for triple antiplatelet therapy in acute coronary syndromes
Beau M Hawkins, Jorge F Saucedo, Sunil V Rao
Review Article: Clinical Investigation
-
The rationale and evidence for triple antiplatelet therapy in acute coronary syndromes
Beau M Hawkins, Jorge F Saucedo, Sunil V Rao
Review Article: Clinical Investigation
-
The rationale and evidence for triple antiplatelet therapy in acute coronary syndromes
Beau M Hawkins, Jorge F Saucedo, Sunil V Rao
Review Article: Clinical Investigation
-
The rationale and evidence for triple antiplatelet therapy in acute coronary syndromes
Beau M Hawkins, Jorge F Saucedo, Sunil V Rao
Review Article: Clinical Investigation
-
The rationale and evidence for triple antiplatelet therapy in acute coronary syndromes
Beau M Hawkins, Jorge F Saucedo, Sunil V Rao
Review Article: Clinical Investigation
-
The rationale and evidence for triple antiplatelet therapy in acute coronary syndromes
Beau M Hawkins, Jorge F Saucedo, Sunil V Rao
Review Article: Clinical Investigation
-
Velaglucerase alfa in the treatment of Gaucher disease type 1
Thomas A Burrow, Gregory A Grabowski
Review Article: Clinical Investigation
-
Velaglucerase alfa in the treatment of Gaucher disease type 1
Thomas A Burrow, Gregory A Grabowski
Review Article: Clinical Investigation
-
Velaglucerase alfa in the treatment of Gaucher disease type 1
Thomas A Burrow, Gregory A Grabowski
Review Article: Clinical Investigation
-
Velaglucerase alfa in the treatment of Gaucher disease type 1
Thomas A Burrow, Gregory A Grabowski
Review Article: Clinical Investigation
-
Velaglucerase alfa in the treatment of Gaucher disease type 1
Thomas A Burrow, Gregory A Grabowski
Review Article: Clinical Investigation
-
Velaglucerase alfa in the treatment of Gaucher disease type 1
Thomas A Burrow, Gregory A Grabowski
Review Article: Clinical Investigation
-
Velaglucerase alfa in the treatment of Gaucher disease type 1
Thomas A Burrow, Gregory A Grabowski
Review Article: Clinical Investigation
-
Velaglucerase alfa in the treatment of Gaucher disease type 1
Thomas A Burrow, Gregory A Grabowski
Review Article: Clinical Investigation